Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · AARTIDRUGS

AARTI DRUGS

HealthcarePharmaceuticals & Biotechnology₹4618 cr market cap
₹499.45 ▼ -1.25% today As of 19 Nov 2026
52-week low ₹319.7552-week high ₹508.75

-0.6% from the 52-week high · +58.2% above the low

Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,500 full-time employees. The firm operates through pharmaceuticals segment. The firm's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The firm's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.

The short version. AARTI DRUGS reported revenue of ₹826 crore for Sep 2026, up 26.5% from a year earlier. Net profit was ₹83 crore (up 84.4% year on year). Return on equity was 12.6% in Mar 2026. Promoter holding was 54.07% in Sep 2026, down 1.31 points over 8 quarters.

1 · The price

How has the stock traded?

AARTI DRUGS trades 0.6% below its 52-week high and 58.2% above its 52-week low.

Change over period: —

1M+26.7%
3M+23.8%
6M+32.5%
1Y+12.1%

2 · The business

Is it growing?

Sales, year on year+26.5%

Sep 2026 revenue of ₹826 cr.

Profit, year on year+84.4%

Sep 2026 net profit of ₹83 cr.

Net margin10.0%

3.1 pts higher than a year earlier.

3-year growth5.4% profit

Revenue compounded at -1.9% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue826703720602653591677557
Net profit8350554145546337
Net margin %10.07.17.76.76.99.19.36.7
EPS (₹)9.095.56.054.444.965.916.894.06

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue25652387252927162489215518061561
Net profit19516817116620528014190
Net margin %7.67.06.86.18.213.07.85.7
EPS (₹)21.3618.4218.6517.9622.1430.0915.179.51

3 · The quality

How well does it turn capital into profit?

Return on equity was 12.6% in Mar 2026; debt to equity is 0.37.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %12.612.313.414.0
Return on capital %12.914.216.417.3
EBITDA margin %12.112.612.711.3
Net margin %7.67.06.86.1

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR-1.9%3.5%
Profit CAGR5.4%-7.0%
Debt to equity0.37
Interest cover7.3x
Current ratio1.59
P/E ratio20.3

4 · The owners

Who holds it, and are they adding?

Promoter holding54.07%

Down 1.31 pts over 8 quarters.

Foreign institutions2.26%

Down 0.02 pts over 8 quarters.

Domestic institutions10.24%

Up 1.47 pts over 8 quarters.

Mutual fund schemes8

+2 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter55.3855.4855.2254.7255.0355.0354.4354.07-1.31
FII2.282.252.262.692.151.581.522.26-0.02
DII8.779.79.949.910.1210.2210.2910.24+1.47
Public33.5732.5732.5832.6932.733.1833.7533.43-0.14

Mutual fund holdings · Oct 2026

8 schemes hold this stock

6 the month before.

  • DSP Small Cap Fund1.37% of NAV
  • ICICI Prudential Healthcare Fund1.0% of NAV
  • DSP Healthcare Fund1.0% of NAV
  • Bandhan BSE Healthcare Index Fund0.1% of NAV
  • Motilal Oswal BSE Healthcare ETF0.1% of NAV
  • Motilal Oswal BSE 1000 Index Fund0.01% of NAV
  • ADITYA BIRLA SUN LIFE BSE TOTAL MARKET INDEX FUND0.01% of NAV
  • ADITYA BIRLA SUN LIFE BSE TOTAL MARKET ETF0.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for AARTI DRUGS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about AARTI DRUGS

What is the AARTI DRUGS share price?

AARTI DRUGS (AARTIDRUGS) last closed at ₹499.45, down 1.25% on the day. Its 52-week range is ₹319.75 to ₹508.75.

What is the market cap of AARTI DRUGS?

AARTI DRUGS has a market capitalisation of about ₹4,618 crore. Its price-to-earnings ratio is 20.3.

How are AARTI DRUGS's latest results?

AARTI DRUGS reported revenue of ₹826 crore for Sep 2026, up 26.5% from a year earlier. Net profit was ₹83 crore (up 84.4% year on year). Return on equity was 12.6% in Mar 2026. Promoter holding was 54.07% in Sep 2026, down 1.31 points over 8 quarters.

Who owns AARTI DRUGS?

As of Sep 2026, shareholding was: Promoter 54.07%, FII 2.26%, DII 10.24%, Public 33.43%.

How many mutual funds hold AARTI DRUGS?

8 mutual fund schemes held AARTI DRUGS in October 2026. That compares with 6 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 09 Feb 2026 · Interim Dividend - Rs. 2
  • 04 Feb 2025 · Interim Dividend - Rs. 1
  • 06 Feb 2024 · Interim Dividend - Rs. 1
  • 08 Feb 2023 · Interim Dividend - Rs. 1
  • 09 Feb 2022 · Interim Dividend - Rs. 1
  • 03 Nov 2020 · Interim Dividend - Rs. 2.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.